News Third indication beckons for Amgen's Uplizna Amgen is preparing to file a third indication for Uplizna, as a twice-yearly therapy for generalised myasthenia gravis, following new phase 3 data.
News Insilico raises $110m for AI-designed drug pipeline Insilico Medicine has raised $110 million in Series E funding for its artificial intelligence-powered drug discovery operations.
News Roche builds in obesity with $5.3bn Zealand licensing deal Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.
News Pfizer's new drug data in breast cancer draws muted response Pfizer and Arvinas' much-anticipated oral SERD vepdegestrant for breast cancer missed a key endpoint in its first phase 3 readout.
News Scientific 'superintelligence' firm Lila launches with $200m Lila Sciences has emerged with $200m in seed financing to advance its vision of AI-powered, fully autonomous labs to power scientific advances.
News J&J abandons work with Genmab on Darzalex successor Genmab is facing increased pressure to deliver on its in-house pipeline after Johnson & Johnson exited a partnership on a Darzalex follow-up.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.